|
|||||
|
|
EPZ011989, A Potent,Orally-Available EZH2 Inhibitor with Robust in Vivo Activity |
||
| Authors: | John E. Campbell,Kevin W. Kuntz,Sarah K. Knutson,Natalie M. Warholic,Heike Keilhack,Tim J. Wigle,Alejandra Raimondi,Christine R. Klaus,Nathalie Rioux,Akira Yokoi,Satoshi Kawano,Yukinori Minoshima,Hyeong-Wook Choi,Margaret Porter Scott,Nigel J. Waters,Jesse J. Smith,Richard Chesworth,Mikel P. Moyer,Robert A. Copeland | |
| Affiliation: | †Epizyme, Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States;‡Eisai Co., Ltd., Tokodai 5-1-3, Tsukuba, Ibarakai 300-2635, Japan;§Eisai, Inc., 4 Corporate Drive, Andover, Massachusetts 01810, United States | |
| Abstract: | ||
| Keywords: | Methyltransferase PRC2 EZH2 B cell lymphoma KARPAS-422 xenograft in vivo chemical probe | |